Summary
With a steadily growing, aging population, there is significant strain on the pharmaceutical sector to produce state of the art therapeutics for societal needs whilst respecting the finite resources provided by the environment. Prominent advances in drug design are reliant on chemical synthesis platforms allowing the efficient exploration of chemical space to discover next generation functional molecules. As a result, innovation is currently limited by the practical implementation of enabling methods, which often becomes the rate limiting factor in cutting-edge research: this is more pronounced when translating academic research to industrial settings. The current renaissance of organic photochemistry and light-driven processes in a broader sense provide an opportunity to reconcile the growing demand for new functional molecules with consideration of sustainability and atom economy. Inspired by the importance of organoboron motifs in medicinal chemistry, this EU action “LUMIBOR” will harness the untapped potential of boron hybridization and boron ligand design to unlock new excited state reactivity paradigms and thereby facilitate the discovery of new methods to access achiral and chiral 3D organoboron scaffolds. LUMIBOR will create a structural platform to utilize boron hybridization in the development of next generation light-enabled ACTIVATION methods. Understanding the correlation between hybridization and parameters such as excited state energy and adjacent bond dissociation energy will allow access to synthetically versatile, high-energy intermediates such as α-boryl radicals and the triplet excited state. Strategic control over boron hybridization will also be utilized to regulate REACTIVITY, by influencing radical philicty, spin density, and excited state lifetimes among other parameters. Collectively, LUMIBOR will create expansive guidelines to expand the synthesis arsenal by developing novel platforms to construct desirable 3D organoboron molecules.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101163783 |
| Start date: | 01-01-2025 |
| End date: | 31-12-2029 |
| Total budget - Public funding: | 1 457 385,00 Euro - 1 457 385,00 Euro |
Cordis data
Original description
With a steadily growing, aging population, there is significant strain on the pharmaceutical sector to produce state of the art therapeutics for societal needs whilst respecting the finite resources provided by the environment. Prominent advances in drug design are reliant on chemical synthesis platforms allowing the efficient exploration of chemical space to discover next generation functional molecules. As a result, innovation is currently limited by the practical implementation of enabling methods, which often becomes the rate limiting factor in cutting-edge research: this is more pronounced when translating academic research to industrial settings. The current renaissance of organic photochemistry and light-driven processes in a broader sense provide an opportunity to reconcile the growing demand for new functional molecules with consideration of sustainability and atom economy. Inspired by the importance of organoboron motifs in medicinal chemistry, this EU action “LUMIBOR” will harness the untapped potential of boron hybridization and boron ligand design to unlock new excited state reactivity paradigms and thereby facilitate the discovery of new methods to access achiral and chiral 3D organoboron scaffolds. LUMIBOR will create a structural platform to utilize boron hybridization in the development of next generation light-enabled ACTIVATION methods. Understanding the correlation between hybridization and parameters such as excited state energy and adjacent bond dissociation energy will allow access to synthetically versatile, high-energy intermediates such as α-boryl radicals and the triplet excited state. Strategic control over boron hybridization will also be utilized to regulate REACTIVITY, by influencing radical philicty, spin density, and excited state lifetimes among other parameters. Collectively, LUMIBOR will create expansive guidelines to expand the synthesis arsenal by developing novel platforms to construct desirable 3D organoboron molecules.Status
SIGNEDCall topic
ERC-2024-STGUpdate Date
21-11-2024
Images
No images available.
Geographical location(s)
